Independent Review of the 52nd Annual EASL



About the Program

Program Overview

The Advances in Chronic Hepatitis C: Management and Treatment program is a comprehensive, expert review of the 52nd Annual Meeting of the European Association for the Study of the Liver (EASL 2017). This program will feature HCV experts reviewing and discussing the most important studies on chronic hepatitis C presented at EASL 2017. This review and discussion will provide a comprehensive overview of each of the posters and presentations as selected by our faculty panel. In addition, the faculty will provide unique insights into how knowledgeable experts review and analyze data from EASL and an in-depth understanding of the scientific quality and clinical relevance of the posters and presentations reviewed.

This activity will enable participating health care providers caring for HCV-infected patients to become aware of and understand the data presented at this important conference and appropriately utilize those data to improve patient care.

Back to Top   

Target Audience

This activity has been designed to meet the educational needs of physicians, physician assistants, advanced practice nurses and other health care professionals involved in the care of patients with HCV infection.

Back to Top

Learning Objectives

After completing this activity, the participant should be better able to:

  • Use in a clinical setting important findings from key studies on CHC diagnosis and treatment presented at EASL 2017 

  • Employ the current treatment paradigms for CHC, including the studies and data presented at EASL 2017, to improve patient care

  • Discuss with patients and colleagues the studies and data on newer therapies for CHC presented at EASL 2017 to decide on appropriate planning of therapy for patients with CHC

Release Date:  May 1, 2017

Expiration Date:  May 1, 2018

Estimated time to complete this program:  2 hours

Media: Internet

Back to Top

Course Director

Mark Sulkowski, MD
Professor of Medicine and Medical Director
Viral Hepatitis Center
Johns Hopkins University School of Medicine
Baltimore, Maryland


Nezam H. Afdhal, MD
Professor of Medicine
Harvard School of Medicine
Chief of Hepatology, Director of Liver Center
Beth Israel Deaconess Medical Center
Boston, Massachusetts

Fred Poordad, MD
VP, Academic and Clinical Affairs
The Texas Liver Institute
Clinical Professor of Medicine
University of Texas Health Science Center
San Antonio, Texas

Jürgen Rockstroh, MD
Professor of Medicine
Department of Medicine I
University Hospital
Bonn, Germany 

Back to Top  

Physician Continuing Medical Education

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and ViralEd, Inc. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s). Physicians should claim only the credit commensurate with the extent of their participation in the activity. There will be 8 posters and presentations available for a total of 2.00 possible credit hours.

Back to Top

European Continuous Medical Education

AMA PRA Category 1 Credits™ claimed by physicians attending live events certified and organized in the United States for AMA PRA Category 1 Credits™ can be claimed through the agreement on mutual recognition of credits between UEMS and AMA, considered as being equal to the European Continuous Medical Education Credits (ECMEC®) granted by the UEMS. One AMA PRA Category 1 Credit™ is equivalent to one (1) hour of European EACCME Credit (ECMEC®), therefore up to 1.0 ECMEC® Credits are available.

Back to Top

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:


Nezam Afdhal, MD

  • Consulting Fees: Merck, Gilead, Echosens, Ligand, Janssen, Shionogi
  • Employee/Salary: Sprint Bank Pharmaceuticals (Research Company)
  • Other: Director-TRIO Healthcare
  • Stock: Allurion, Spring Bank Pharmaceuticals
  • Stock Options: SpringBank Pharmaceuticals, TRIO

Fred Poordad, MD

  • Consulting Fees: Abbvie, Gilead, Merck, BMS, Salix
  • Fees for Non-CME/CE Services Received Directly from a Commercial Interest or thier Agents: Abbvie, Gilead, Merck, BMS, Salix
  • Research Support: Abbvie, Gilead, Merck, BMS, Salix

Juergen Rockstroh, MD

  • Consulting Fees: Abbott, Gilead, Hexal, Merck, ViiV
  • Fees for Non-CME/CE Services Received Directly from a Commercial Interest or thier Agents: Abbott, Gilead, Janssen, Merck
  • Contracted Research: Gilead

Mark Sulkowski, MD

  • Contracted Research (to JHU): Abbvie, Gilead, Merck, Tobira
  • Consulting Fees: Abbvie, CoCrystal, Gilead, Janssen, Merck, Trek
  • Other: Gilead - DSMB Member

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

The PIM planners and managers, Trace Hutchison, PharmD, Samantha Mattucci, PharmD, CHCP, Judi Smelker-Mitchek, MBA, MSN, RN and Jan Schultz, MSN, RN, CHCP, have nothing to disclose.

Instructions for Participation and Credit

There are no fees for participating and receved CME credit for this activity.  During the period, May 1, 2017 through May 1, 2018, participants must read the learning objectives and faculty disclosures and study the educational activity.

PIM supports Green CME by offering your Request for Credit online. If you wish to received acknowledgment of completing this activity, please complete the post-test and evaluation on On the navigation menu, click on "Find Post-test/Evaluation by Course" and search by course ID 12485.  Upon registering and successfully completing the post-test with a score of 70% or better and the activity evaluation, your certificate will be made available immediately.  Processing credit requests online will reduce the amount of paper used by nearly 100,000 sheets per year.


Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.  

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners.  Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Back to Top


Poster/Presentation Listing

 EASL17_Abst_PS-098.jpg HBV/HIV Co-Infection - LDV/SOF for 12 Weeks Is Safe and Effective in Patients
with Chronic Hepatitis C and Hepatitis B Coinfection - A Phase 3 Study in Taiwan
 EASL 17-ab 130 Treatment of Persons Who Inject Drugs - The PREVAIL Study
 EASL 19- ab 156 DAA Failures - MAGELLAN-1, Part 2: Glecaprevir/Pibrentasvir for 12 or 16 Weeks in Patients with Chronic HCV Genotype 1 or 4 and Prior DAA Treatment Failure

New Data with Glecaprevir/Pibrentasvir - Expedition 1 and 2 and Endurance 3 Studies

 EASL17_Abst_PS-125.jpg HCV Elimination - Projected Impact and Pathways to Success of
the Hepatitis C Virus Elimination Program in Georgia, 2015-2020
 EASL 6-ps035  HCC Risk Post-SVR - Among Cirrhotic Patients with an HCV SVR, the Risk of De-Novo HCC Relates to Baseline Factors and Not the Use of DAAs: Results from a Nationwide Cohort
 EASL 7-ps159  New Data with Grazoprevir + Ruzasvir + Uprifosbuvir - C-SURGE Study
 EASL 8-ps095

Real World Effectiveness - Real World Experience with Elbasvir/Grazoprevir in the Veterans Affairs Healthcare System



Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities. 

Back to Top






This activity is supported by an independent medical educational grant from Merck & Co.

This coverage is not sanctioned by the conference organizers and is not an official part of the conference proceedings.


Prepare to print

Share this page:

Get link code to this page     

Back to Top